STOCK TITAN
  1. Home
  2. Sec-filings
  3. SNDX
  4. [144] Syndax Pharmaceuticals, Inc. SEC Filing

[144] Syndax Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock SNDX logo
Syndax Pharmaceuticals Inc

NASDAQ:SNDX

SNDX Rankings

#3344 Ranked by Market Cap
N/A Ranked by Dividends

SNDX Latest News

Jul 2, 2025
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jun 24, 2025
Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia
Jun 12, 2025
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025
Jun 12, 2025
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
Jun 5, 2025
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SNDX Latest SEC Filings

Jul 18, 2025
[Form 4] Syndax Pharmaceuticals, Inc. Insider Trading Activity
Jul 18, 2025
[Form 4] Syndax Pharmaceuticals, Inc. Insider Trading Activity
Jul 16, 2025
[144] Syndax Pharmaceuticals, Inc. SEC Filing
Jul 10, 2025
[144] Syndax Pharmaceuticals, Inc. SEC Filing
Jun 26, 2025
[8-K] Syndax Pharmaceuticals, Inc. Reports Material Event

SNDX Stock Data

844.99M
84.91M
1.3%
116.29%
22.32%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK